Creating new treatments for hemophilia A by improving factor VIII production
Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII
This study is looking at new ways to help people with hemophilia A by testing small drugs that can boost a key protein needed for blood clotting and exploring gene therapy options to provide longer-lasting solutions, making treatments easier and more affordable for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11047704 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for hemophilia A, a genetic disorder that affects blood clotting. The approach involves using small molecule drugs to enhance the production and function of the factor VIII protein, which is often deficient or dysfunctional in patients with this condition. By targeting specific mutations that cause hemophilia A, the research aims to improve patient access to effective treatments that are more affordable and easier to administer than current therapies. The study also explores the potential of gene therapy using adeno-associated viruses to provide long-term solutions for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are males diagnosed with hemophilia A, particularly those with specific mutations affecting factor VIII production.
Not a fit: Patients with hemophilia B or those who do not have mutations in the factor VIII gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accessible and effective treatments for hemophilia A, improving the quality of life for patients.
How similar studies have performed: Previous research has shown promise in using small molecules and gene therapy for similar genetic disorders, indicating a potential for success in this approach.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Zhang, Bin — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Zhang, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.